{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T04:01:40Z","timestamp":1777003300091,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T00:00:00Z","timestamp":1544745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Wales Gene Park"},{"DOI":"10.13039\/501100000311","name":"Tuberous Sclerosis Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000311","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Wales Gene Park"},{"DOI":"10.13039\/501100000311","name":"Tuberous Sclerosis Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000311","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.neo.2018.12.003","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T22:33:44Z","timestamp":1546986824000},"page":"230-238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy of Dual Inhibition of Glycolysis and Glutaminolysis for Therapy of Renal Lesions in Tsc2+\/\u2212 Mice"],"prefix":"10.1016","volume":"21","author":[{"given":"Ashley T.","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalin","family":"Narov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian R.","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming Hong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.neo.2018.12.003_bb0005","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/0092-8674(93)90618-Z","article-title":"Identification and characterization of the tuberous sclerosis gene on chromosome 16","volume":"75","author":"Consortium ECTS","year":"1993","journal-title":"Cell"},{"issue":"Pt 1","key":"10.1016\/j.neo.2018.12.003_bb0010","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1042\/BST0370217","article-title":"A complex interplay between Akt, TSC2 and the two mTOR complexes","volume":"37","author":"Huang","year":"2009","journal-title":"Biochem Soc Trans"},{"issue":"6","key":"10.1016\/j.neo.2018.12.003_bb0015","first-page":"1639","article-title":"Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors","volume":"151","author":"Henske","year":"1997","journal-title":"Am J Pathol"},{"issue":"7","key":"10.1016\/j.neo.2018.12.003_bb0020","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1093\/hmg\/ddu597","article-title":"A shower of second hit events as the cause of multifocal renal cell carcinoma in tuberous sclerosis complex","volume":"24","author":"Tyburczy","year":"2015","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/j.neo.2018.12.003_bb0025","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.neo.2018.12.003_bb0030","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1158\/1078-0432.CCR-11-0445","article-title":"Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis","volume":"17","author":"Davies","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"9869","key":"10.1016\/j.neo.2018.12.003_bb0035","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.neo.2018.12.003_bb0040","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.molcel.2010.05.007","article-title":"Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply","volume":"38","author":"Choo","year":"2010","journal-title":"Mol Cell"},{"issue":"4","key":"10.1016\/j.neo.2018.12.003_bb0045","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.cell.2013.04.023","article-title":"The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4","volume":"153","author":"Csibi","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.neo.2018.12.003_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2045-3701-1-34","article-title":"Glucose deprivation in tuberous sclerosis complex-related tumors","volume":"1","author":"Jiang","year":"2011","journal-title":"Cell Biosci"},{"issue":"1","key":"10.1016\/j.neo.2018.12.003_bb0055","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10863-012-9420-9","article-title":"Over-expression of GAPDH in human colorectal carcinoma as a preferred target of 3-bromopyruvate propyl ester","volume":"44","author":"Tang","year":"2012","journal-title":"J Bioenerg Biomembr"},{"issue":"1","key":"10.1016\/j.neo.2018.12.003_bb0060","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10863-012-9417-4","article-title":"A translational study \"case report\" on the small molecule \"energy blocker\" 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside","volume":"44","author":"Ko","year":"2012","journal-title":"J Bioenerg Biomembr"},{"issue":"4","key":"10.1016\/j.neo.2018.12.003_bb0065","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1535-7163.MCT-13-0870","article-title":"Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer","volume":"13","author":"Gross","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"21","key":"10.1016\/j.neo.2018.12.003_bb0070","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1182\/blood.V124.21.3763.3763","article-title":"Efficacy of novel glutaminase inhibitor CB-839 in acute myeloid leukemia","volume":"124","author":"Matre","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.neo.2018.12.003_bb0075","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1172\/JCI75836","article-title":"Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis","volume":"125","author":"Xiang","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.neo.2018.12.003_bb0080","series-title":"Keystone Symposia","article-title":"CB-839, a selective glutaminase inhibitor, has anti-tumor activity in renal cell carcinoma and synergizes with cabozantinib and everolimus","author":"Emberley","year":"2017"},{"issue":"6","key":"10.1016\/j.neo.2018.12.003_bb0085","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI7319","article-title":"Tsc2(+\/\u2212) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background","volume":"104","author":"Onda","year":"1999","journal-title":"J Clin Investig"},{"issue":"9","key":"10.1016\/j.neo.2018.12.003_bb0090","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/j.ejrad.2011.06.054","article-title":"T2 weighted MRI for assessing renal lesions in transgenic mouse models of tuberous sclerosis","volume":"81","author":"Kalogerou","year":"2012","journal-title":"Eur J Radiol"},{"issue":"7","key":"10.1016\/j.neo.2018.12.003_bb0095","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/onc.2014.17","article-title":"Renal tumours in a Tsc2(+\/\u2212) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin","volume":"34","author":"Yang","year":"2015","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.neo.2018.12.003_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032043","article-title":"System-wide immunohistochemical analysis of protein co-localization","volume":"7","author":"Kim","year":"2012","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.neo.2018.12.003_bb0105","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/onc.2014.17","article-title":"Renal tumours in a Tsc2(+\/\u2212) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin","volume":"34","author":"Birsoy","year":"2015","journal-title":"Oncogene"},{"issue":"35","key":"10.1016\/j.neo.2018.12.003_bb0110","doi-asserted-by":"crossref","first-page":"58504","DOI":"10.18632\/oncotarget.17215","article-title":"The dual PI3KmTOR inhibitor GSK2126458 is effective for treating solid renal tumours in Tsc2+\u2212 mice through suppression of cell proliferation and induction of apoptosis","volume":"8","author":"Narov","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.neo.2018.12.003_bb0115","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nrc2981","article-title":"Regulation of cancer cell metabolism","volume":"11","author":"Cairns","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.neo.2018.12.003_bb0120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrclinonc.2016.60","article-title":"Cancer metabolism: a therapeutic perspective","volume":"14","author":"Martinez-Outschoorn","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.neo.2018.12.003_bb0125","doi-asserted-by":"crossref","first-page":"494","DOI":"10.2174\/1568026618666180523111351","article-title":"Inhibition of glycolysis and glutaminolysis: an emerging drug discovery approach to combat cancer","volume":"18","author":"Akins","year":"2018","journal-title":"Curr Top Med Chem"},{"issue":"38","key":"10.1016\/j.neo.2018.12.003_bb0130","doi-asserted-by":"crossref","first-page":"63551","DOI":"10.18632\/oncotarget.18854","article-title":"Dual inhibition of glycolysis and glutaminolysis as a therapeutic strategy in the treatment of ovarian cancer","volume":"8","author":"Sun","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.neo.2018.12.003_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-015-0399-9","article-title":"3-BrPA eliminates human bladder cancer cells with highly oncogenic signatures via engagement of specific death programs and perturbation of multiple signaling and metabolic determinants","volume":"14","author":"Konstantakou","year":"2015","journal-title":"Mol Cancer"},{"issue":"4","key":"10.1016\/j.neo.2018.12.003_bb0140","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.3892\/or.2015.4147","article-title":"Inhibitory effects of 3-bromopyruvate in human nasopharyngeal carcinoma cells","volume":"34","author":"Zou","year":"2015","journal-title":"Oncol Rep"},{"key":"10.1016\/j.neo.2018.12.003_bb0145","doi-asserted-by":"crossref","first-page":"e1585","DOI":"10.1038\/cddis.2014.545","article-title":"Primary clear cell renal carcinoma cells display minimal mitochondrial respiratory capacity resulting in pronounced sensitivity to glycolytic inhibition by 3-bromopyruvate","volume":"6","author":"Nilsson","year":"2015","journal-title":"Cell Death Dis"},{"issue":"23","key":"10.1016\/j.neo.2018.12.003_bb0150","doi-asserted-by":"crossref","first-page":"6746","DOI":"10.1158\/0008-5472.CAN-17-0930","article-title":"Glutamine addiction in kidney cancer suppresses oxidative stress and can be exploited for real-time imaging","volume":"77","author":"Abu Aboud","year":"2017","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.neo.2018.12.003_bb0155","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/phar.2076","article-title":"Cabozantinib: a multitargeted oral tyrosine kinase inhibitor","volume":"38","author":"Markowitz","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"8","key":"10.1016\/j.neo.2018.12.003_bb0160","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/ijc.29225","article-title":"Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model","volume":"136","author":"Song","year":"2015","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.neo.2018.12.003_bb0165","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/1756287217748867","article-title":"Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience","volume":"10","author":"Osanto","year":"2018","journal-title":"Ther Adv Urol"},{"issue":"2","key":"10.1016\/j.neo.2018.12.003_bb0170","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neo.2016.12.008","article-title":"Combination of everolimus with sorafenib for solid renal tumors in Tsc2(+\/\u2212) mice is superior to everolimus alone","volume":"19","author":"Yang","year":"2017","journal-title":"Neoplasia"},{"issue":"13","key":"10.1016\/j.neo.2018.12.003_bb0175","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","article-title":"Rapamycin induces feedback activation of Akt signaling through an IGF-1R\u2013dependent mechanism","volume":"26","author":"Wan","year":"2007","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.neo.2018.12.003_bb0180","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1128\/MCB.01061-10","article-title":"xmTORC2 is required for proliferation and survival of TSC2-null cells","volume":"31","author":"Goncharova","year":"2011","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.neo.2018.12.003_bb0185","doi-asserted-by":"crossref","DOI":"10.1038\/cddiscovery.2015.16","article-title":"mTORC2 controls cancer cell survival by modulating gluconeogenesis","volume":"1","author":"Khan","year":"2015","journal-title":"Cell Death Discov"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147655861830575X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147655861830575X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T15:59:35Z","timestamp":1573660775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147655861830575X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S147655861830575X"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2018.12.003","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Dual Inhibition of Glycolysis and Glutaminolysis for Therapy of Renal Lesions in Tsc2+\/\u2212 Mice","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2018.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc.","name":"copyright","label":"Copyright"}]}}